Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1b/2a trial to investigate safety and efficacy of tesevatinib for the treatment of Autosomal Recessive Polycystic Kidney disease (ARPKD) in newborns

Next Previous
Trial Profile

A phase 1b/2a trial to investigate safety and efficacy of tesevatinib for the treatment of Autosomal Recessive Polycystic Kidney disease (ARPKD) in newborns

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 08 Aug 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tesevatinib (Primary)
  • Indications Autosomal recessive polycystic kidney disease
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 03 Aug 2017 According to a Kadmon Corporation media release, the company expects to initiate this trial in third quarter of 2017.
  • 22 Mar 2017 According to a Kadmon Corporation media release, the company anticipates to initiate this study in the second quarter of 2017.
  • 19 Nov 2016 According to a Kadmon Corporation media release, the company anticipates to initiate this study in the year 2017.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top